Literature DB >> 33593687

IL-37 overexpression enhances the therapeutic effect of endometrial regenerative cells in concanavalin A-induced hepatitis.

Guangming Li1, Dejun Kong1, Yafei Qin1, Hongda Wang1, Yonghao Hu1, Yiming Zhao1, Jingpeng Hao1, Hong Qin1, Dingding Yu1, Yanglin Zhu1, Chenglu Sun1, Hao Wang2.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells and immunosuppressive factor IL-37 can both suppress concanavalin A (Con A)-induced hepatitis in mice. Endometrial regenerative cells (ERCs), novel types of mesenchymal-like stromal cells, possess powerful immunomodulatory effects and are effective in treating various diseases. The aim of this study was to explore the effects of ERCs in suppressing Con A-induced hepatitis and determine whether IL-37 overexpression could enhance the therapeutic effect of ERCs in this process.
METHODS: ERCs were extracted from the menstrual blood of healthy female volunteer donors. The IL-37 gene was transferred into ERCs, and the expression of IL-37 in cells was detected by western blot and enzyme-linked immunosorbent assay. Hepatitis was induced by Con A in C57BL/6 mice that were randomly divided into groups treated with phosphate-buffered saline, ERCs, IL-37 or ERCs transfected with the IL-37 gene (IL-37-ERCs). Cell tracking, liver function, histopathological and immunohistological changes, immune cell proportions and levels of cytokines were measured 24 h after Con A administration.
RESULTS: Compared with ERC or IL-37 treatment, IL-37-ERCs further reduced levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase) and improved histopathological changes in the liver. In addition, IL-37-ERC treatment further reduced the proportions of M1 macrophages and CD4+ T cells and increased the proportion of regulatory T cells. Moreover, IL-37-ERC treatment resulted in lower levels of IL-12 and interferon gamma, and higher level of transforming growth factor beta.
CONCLUSIONS: The results of this study suggest that ERCs can effectively alleviate Con A-induced hepatitis. Furthermore, IL-37 overexpression can significantly enhance the therapeutic efficacy of ERCs by augmenting the immunomodulatory and anti-inflammatory properties of ERCs. This study may provide a promising strategy for treatment of T-cell-dependent hepatitis.
Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-37; T-cell-dependent liver injury; concanavalin A-induced hepatitis; endometrial regenerative cells

Mesh:

Substances:

Year:  2021        PMID: 33593687     DOI: 10.1016/j.jcyt.2020.12.006

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

1.  IL-37 overexpression promotes endometrial regenerative cell-mediated inhibition of cardiac allograft rejection.

Authors:  Hong Qin; Chenglu Sun; Yanglin Zhu; Yafei Qin; Shaohua Ren; Zhaobo Wang; Chuan Li; Xiang Li; Baoren Zhang; Jingpeng Hao; Guangming Li; Hongda Wang; Bo Shao; Jingyi Zhang; Hao Wang
Journal:  Stem Cell Res Ther       Date:  2022-07-15       Impact factor: 8.079

2.  Concanavalin A promotes angiogenesis and proliferation in endothelial cells through the Akt/ERK/Cyclin D1 axis.

Authors:  Jing-Zhou Li; Xiao-Xia Zhou; Wei-Yin Wu; Hai-Feng Qiang; Guo-Sheng Xiao; Yan Wang; Gang Li
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

3.  Endometrial Regenerative Cell-Derived Conditioned Medium Alleviates Experimental Colitis.

Authors:  Chenglu Sun; Jingpeng Hao; Hong Qin; Yanglin Zhu; Xiang Li; Baoren Zhang; Yafei Qin; Guangming Li; Hongda Wang; Hao Wang
Journal:  Stem Cells Int       Date:  2022-01-27       Impact factor: 5.443

4.  Protective Effects of Interleukin-37 Expression against Acetaminophen-Induced Hepatotoxicity in Mice.

Authors:  Zhiwei Xu; Kan Li; Xiuhe Pan; Jun Tan; Yan Li; Mingcai Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-04       Impact factor: 2.629

5.  Moscatilin suppresses the inflammation from macrophages and T cells.

Authors:  Ying Zhang; Yugang Xu; Xiujie Jing; Wenkui Lu; Fusen Zhang; Chengkun Qin
Journal:  Open Med (Wars)       Date:  2022-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.